Skyhawk Therapeutics
John McKeague has worked in a variety of legal and scientific roles since 2004. John began their career as a Biologist at the NIH, then worked as a Patent Agent at Patton Boggs LLP, followed by a Patent Law Clerk at Pillsbury Winthrop Shaw Pittman. In 2007, they returned to Patton Boggs LLP as an Associate and then moved to Norbrook Laboratories Ltd. in 2011 as a Patent Executive. In 2013, they started their own practice as a US Patent Attorney and then joined Buchanan Ingersoll & Rooney PC in 2014 as an Associate. John was then Principal and Counsel at Porzio Bromberg & Newman P.C. from 2014 to 2019, followed by Of Counsel at Wilson Sonsini Goodrich & Rosati from 2019 to 2020. John is currently Vice President Legal at Skyhawk Therapeutics.
John McKeague completed their B.Sc. in Biomedical Sciences from Ulster University between 1994 and 1998. John then went on to pursue a Ph.D. in Biomedical Sciences from Ulster University, which they completed in 2003. In 2004, they enrolled in The George Washington University Law School, where they earned their JD in 2008.
This person is not in any offices
Skyhawk Therapeutics
1 followers
At Skyhawk Therapeutics we invent small molecules using proprietary kinetic, structural and computational models that correct RNA splicing and mis-spicing. Our small molecule platform accelerates drug development across a broad range of disease types.